Skip to main content

Virtual Molecular Rounds

March to December, 2024


Next Round: Thursday, March 14, 2024



POET National Virtual Molecular Rounds is a one hour monthly educational program which takes place at 10AM MT/ 9AM PT / 12 noon ET/ 1PM ATL.

POET is an academic program based out of the University of Calgary focused on Precision Oncology biomarker discovery, registries and access to novel diagnostics and therapeutics. POET strives to have accessible education across Canada for health care clinicians about molecular diagnostics and advancements in precision oncology biomarker driven practice.

By the end of the webinar series, each audience member will have the opportunity to:

  1. Learn the latest developments in molecular oncology and precision medicine through world-renowned speakers.
  2. Discuss and understand approaches to the challenging clinical interpretation of comprehensive genomic profile results shared among experts.
  3. Discuss areas of controversy and the challenges of molecular and polyomic diagnostics in relation to biomarker driven precision oncology therapeutics.

We look forward to this very informative virtual webinar series.

Best regards,

Dr. Pinaki Bose
Scientific Lead, POET Molecular Rounds

Dr. Steven Yip
Medical Lead, POET Molecular Rounds

Dr. Vishal Navani,
Principal POET Ambassador,
Virtual Molecular Rounds 


POSTPONED – Thursday, February 15th, 2024
(Times listed in Mountain Time)
10:00 AM – 10:05 AM Welcome Remarks Dr. Steven Yip & Dr. Vishal Navani, POET VMR Co-Chairs
10:05 AM – 10:50 AM Adjuvant Therapy for Renal Cell Cancer

Learning Objectives:

  1. Understand the clinical need for adjuvant therapy in renal cell cancer
  2. Understand what factors increase the risk of relapse of renal cell cancer
  3. Gain an overview of adjuvant studies in renal cell cancer prior to checkpoint inhibitors
  4. Gain an overview of checkpoint inhibitor adjuvant studies in renal cancer and a more detailed understanding of the Keynote 564 study of adjuvant pembrolizumab
  5. Consider the balance of risks and benefits of treatment for different patient groups
  6. Consider outstanding questions in the adjuvant treatment of renal cell cancer.
Dr. Tim Eisen PhD FRCP FMedSci

Professor of Medical Oncology, University of Cambridge
Global Franchise Head Product Development GI & GU Oncology, Roche
Cambridge, UK

10:50 AM – 10:55 AM Panel Discussion Dr. Steven Yip, Dr. Pinaki Bose & Dr. Vishal Navani
10:55 AM – 11:00 AM Audience Questions & Answers
11:00 AM Closing Remarks Dr. Pinaki Bose & Dr. Steven Yip, POET Chairs